Which trial do we need? Combination antimicrobial therapy for hospital-acquired bacterial pneumonia caused by Pseudomonas aeruginosa

Hospital-acquired bacterial pneumonia (HABP) is the most common healthcare-associated infection in the United States and a leading cause of morbidity, mortality and healthcare expense among hospitalized patients. Pseudomonas aeruginosa (PsA) is the second most common causative pathogen in HABP and a major therapeutic challenge: compared to other pathogens, patients with PsA-HABP experience higher rates of antimicrobial resistance, treatment failure, pneumonia recurrence, and mortality. Improving treatment outcomes for PsA-HABP represents an unmet therapeutic need.